Santarus, Inc. (SNTS) - Financial and Strategic SWOT Analysis Review

Document Sample
Santarus, Inc. (SNTS) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					          Santarus, Inc. (SNTS) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH32757FSA                                                                                          Publication Date: MAR 2013

          3611 Valley Centre Drive, Suite 400                Phone              +1 858 3145700                  Revenue          218 (million USD)
          San Diego, CA                                      Fax                +1 858 3145701                  Net Profit       18.56 (million USD)
          92130                                              Website            www.santarus.com                Employees        290
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           SNTS [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Santarus, Inc. (Santarus) is a specialty biopharmaceutical company. It acquires, develops and commercializing pharmaceutical
       products. The company’s marketed products consists of Uceris (budesonide) extended release tablets 9 mg, Glumetza
       (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) Tablets, Fenoglide (fenofibrate) Tablets
       and Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension. Santarus' product pipeline comprises
       Ruconest (recombinant human C1esterase inhibitor), Rifamycin SV MMX and SAN-300 (anti-VLA-1 antibody).
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Santarus, Inc., SWOT Analysis
         Gerald T. Proehl                    Chief Executive Officer                  Strengths                              Weaknesses
         David F. Hale                       Chairman
                                                                                      Partnerships and Alliances             Legal Proceedings
         Daniel D. Burgess                   Director
                                                                                      Focused Research and                   Business Concentration: The
         Michael G. Carter                   Director
                                                                                      Development Activities                 US
         Michael E. Herman                   Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strong Product Pipeline                Competitive Pressure
         Santarus, Inc.
                                                                                      Growth Prospects: Emerging             Stringent Government
        Share Price (USD) as on 15-Mar-                                16.47          Markets                                Regulations
        2013
        EPS (USD)                                                        0.27
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                       1,053         GlobalData

        Enterprise Value (million USD)                                 1,013
        Shares Outstanding (million)                                       64
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 04, 2013         Santarus Reports Revenue Of $218m In 2012
                                                                                      Nov 07, 2012         Santarus Reports Revenue Of $54.7m In Q3
                                                                                                           2012
                                                                                      Aug 07, 2012         Santarus Reports Revenue Of $47.2m In Q2
                                                                                                           2012
                                                                                      May 08, 2012         Santarus Reports Revenue Of $45.9m In Q1
                                                                                                           2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Santarus, Inc. (SNTS) - Financial and Strategic SWOT Analysis                                                                  Reference Code: GDPH32757FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Santarus, Inc. - Key Facts .................................................................................................................................................................. 5
       Santarus, Inc. - Key Employees ......................................................................................................................................................... 6
       Santarus, Inc. - Key Employee Biographies ....................................................................................................................................... 7
       Santarus, Inc. - Major Products and Services .................................................................................................................................... 8
       Santarus, Inc. - Pharmaceutical Pipeline Products Data .................................................................................................................... 9
          Santarus, Inc., Pipeline Products by Therapy Area ........................................................................................................................ 9
          Santarus, Inc., Pipeline Products by Development Phase ............................................................................................................ 10
       Santarus, Inc. - History ..................................................................................................................................................................... 12
       Santarus, Inc. - Company Statement ............................................................................................................................................... 15
       Santarus, Inc. - Locations And Subsidiaries ..................................................................................................................................... 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       Santarus, Inc. - Business Description............................................................................................................................................... 20
       Santarus, Inc. - Corporate Strategy .................................................................................................................................................. 22
       Santarus, Inc. - SWOT Analysis ....................................................................................................................................................... 23
          SWOT Analysis - Overview........................................................................................................................................................... 23
          Santarus, Inc. - Strengths ............................................................................................................................................................. 23
             Strength - Partnerships and Alliances ....................................................................................................................................... 23
             Strength - Focused Research and Development Activities ....................................................................................................... 23
             Strength - Strong Financial Performance .................................................................................................................................. 23
          Santarus, Inc. - Weaknesses ........................................................................................................................................................ 24
             Weakness - Legal Proceedings ................................................................................................................................................. 24
             Weakness - Business Concentration: The US .......................................................................................................................... 24
          Santarus, Inc. - Opportunities ....................................................................................................................................................... 24
             Opportunity - Strong Product Pipeline ....................................................................................................................................... 24
             Opportunity - Growth Prospects: Emerging Markets ................................................................................................................. 24
             Opportunity - Market Potential: Metabolic Disorders ................................................................................................................. 25
          Santarus, Inc. - Threats ................................................................................................................................................................ 25
             Threat - Competitive Pressure .................................................................................................................................................. 25
             Threat - Stringent Government Regulations .............................................................................................................................. 25
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 25
       Santarus, Inc. - Key Competitors ...................................................................................................................................................... 27
       Section 3 – Company Financial Ratios ............................................................................................................................................. 28
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 28
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 28
       Performance Chart ........................................................................................................................................................................... 30
       Financial Performance...................................................................................................................................................................... 30
       Financial Ratios - Interim Ratios....................................................................................................................................................... 31
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 32
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 33


Santarus, Inc. (SNTS) - Financial and Strategic SWOT Analysis                                                                                                  Reference Code: GDPH32757FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ...................................................................... 33
          Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ..................................................................... 34
       Santarus, Inc., Recent Deals Summary ........................................................................................................................................... 35
       Section 5 – Company’s Recent Developments ................................................................................................................................ 36
          Santarus, Inc., Recent Developments........................................................................................................................................... 36
             Mar 04, 2013: Santarus Reports Revenue Of $218m In 2012 .................................................................................................. 36
             Nov 07, 2012: Santarus Reports Revenue Of $54.7m In Q3 2012 ........................................................................................... 37
             Aug 07, 2012: Santarus Reports Revenue Of $47.2m In Q2 2012 ...................................
				
DOCUMENT INFO
Description: Santarus, Inc. (Santarus) is a specialty biopharmaceutical company. It acquires, develops and commercializing pharmaceutical products. The company’s marketed products consists of Uceris (budesonide) extended release tablets 9 mg, Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) Tablets, Fenoglide (fenofibrate) Tablets and Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension. Santarus' product pipeline comprises Ruconest (recombinant human C1esterase inhibitor), Rifamycin SV MMX and SAN-300 (anti-VLA-1 antibody).
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.